NYSE$ACH
Accendra Health Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Accolade reported Q3 fiscal 2026 net revenue of $697.3M with a net loss from continuing operations of $5.6M and diluted EPS of $(0.07).
Net revenue was $697.3 million while continuing operations posted a net loss of $5.6 million and diluted EPS of $(0.07). The Personalized Health Platform navigated payor contract transitions and elevated acquisition-related costs.
- Q3 net revenue $697.3M.
- Continuing operations net loss $5.6M.
- Major payor contract termination notice creates 2026 transition risk.
- Planned sale of Personal Health Services segment.
Headline financials
Revenue & EPS history
Owens & Minor · Revenue · Quarterly
$697M
Forward guidance
Accolade is transitioning major payor contracts and divesting Personal Health Services while focusing the core platform on employer and health-plan customers.
Tailwinds
- Net revenue growth year over year.
- Personalized Health Platform strategic focus.
- Cost and realignment actions.
Headwinds
- Large payor contract termination in 2026.
- Continuing operations still loss-making.
- Acquisition integration and litigation overhang.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2025
+0.5%
Avg return
Earnings day
-0.2%
Avg return
5 days after
+2.3%
Avg return
30 days after
47%
32 / 68 earnings
Positive
+58.9%
Q2 2019
Best reaction
-37.6%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +8.7% | -18.7% | -23.7% | |
| Q4 2025 | +5.7% | +4.8% | -21.0% | |
| Q3 2025 | -4.8% | -33.1% | -47.9% | |
| Q1 2025 | -9.6% | -6.8% | +3.2% | |
| Q4 2024 | +39.0% | +41.4% | +24.5% | |
| Q3 2024 | -11.7% | -3.4% | +10.3% | |
| Q2 2024 | -9.4% | -9.7% | -5.4% | |
| Q1 2024 | -21.6% | -26.1% | -28.9% | |
| Q4 2023 | +2.7% | +12.6% | +23.1% | |
| Q3 2023 | +25.0% | +19.1% | +39.5% | |
| Q2 2023 | +2.5% | +8.4% | -6.8% | |
| Q1 2023 | +31.2% | +35.7% | +57.4% | |
| Q4 2022 | -21.3% | -13.8% | -28.1% | |
| Q3 2022 | +3.9% | +9.2% | +19.8% | |
| Q2 2022 | -10.8% | -6.7% | -25.8% | |
| Q1 2022 | +10.3% | +4.7% | -5.2% | |
| Q4 2021 | +13.3% | +21.0% | +21.6% | |
| Q3 2021 | +23.8% | +18.3% | +9.5% | |
| Q2 2021 | -16.8% | -16.8% | -16.7% | |
| Q1 2021 | -4.0% | -4.7% | +19.8% | |
| Q4 2020 | +27.8% | +34.3% | +51.3% | |
| Q3 2020 | +1.3% | -2.5% | +0.2% | |
| Q2 2020 | -16.2% | -25.0% | -2.9% | |
| Q1 2020 | -6.3% | -2.9% | +5.6% | |
| Q4 2019 | -12.0% | -30.0% | +0.6% | |
| Q3 2019 | +8.1% | +5.9% | +16.9% | |
| Q2 2019 | +58.9% | +69.1% | +148.1% | |
| Q1 2019 | +7.4% | +7.4% | -27.1% | |
| Q4 2018 | -16.6% | -19.1% | -45.1% | |
| Q3 2018 | -37.6% | -33.9% | -46.3% | |
| Q2 2018 | -21.7% | -24.4% | -5.7% | |
| Q1 2018 | +6.8% | +9.4% | +8.2% | |
| Q4 2017 | +4.4% | +7.6% | +9.3% | |
| Q3 2017 | -24.0% | -21.2% | -23.7% | |
| Q2 2017 | -5.9% | -11.9% | -13.3% | |
| Q1 2017 | -4.8% | -5.4% | -6.3% | |
| Q4 2016 | -2.6% | -2.6% | -2.3% | |
| Q3 2016 | +1.0% | +0.6% | +5.4% | |
| Q2 2016 | -0.1% | -0.1% | -2.3% | |
| Q1 2016 | -2.2% | — | — | |
| Q4 2015 | +7.9% | — | — | |
| Q3 2015 | +1.1% | — | — | |
| Q2 2015 | +5.1% | — | — | |
| Q1 2015 | +3.8% | — | — | |
| Q4 2014 | -3.3% | — | — | |
| Q3 2014 | -2.1% | — | — | |
| Q2 2014 | -2.7% | — | — | |
| Q1 2014 | -2.4% | — | — | |
| Q4 2013 | +3.8% | — | — | |
| Q3 2013 | -1.5% | — | — | |
| Q2 2013 | -3.5% | — | — | |
| Q1 2013 | +6.9% | — | — | |
| Q4 2012 | -1.1% | — | — | |
| Q3 2012 | -1.0% | — | — | |
| Q2 2012 | -6.0% | — | — | |
| Q1 2012 | -2.5% | — | — | |
| Q4 2011 | -0.1% | — | — | |
| Q3 2011 | -1.5% | — | — | |
| Q2 2011 | +0.3% | — | — | |
| Q1 2010 | -0.2% | — | — | |
| Q1 2011 | +2.1% | — | — | |
| Q4 2008 | +2.5% | — | — | |
| Q4 2010 | +2.5% | — | — | |
| Q3 2009 | -1.4% | — | — | |
| Q3 2010 | -1.4% | — | — | |
| Q2 2010 | +2.4% | — | — | |
| Q2 2009 | +2.4% | — | — | |
| Q4 2009 | +2.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro